Clinical Trials in Maumee, Ohio
3 recruiting
Showing 1–16 of 16 trials
Recruiting
Phase 3
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
AstraZeneca675 enrolled281 locationsNCT06357533
Recruiting
Phase 1Phase 2
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
MTAP-deleted Solid Tumors
Servier Bio-Innovation LLC342 enrolled35 locationsNCT06188702
Recruiting
Phase 3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NSCLC (Non-small Cell Lung Cancer)
Revolution Medicines, Inc.420 enrolled129 locationsNCT06881784
Recruiting
Phase 1
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Breast CancerEndometrial CancerAdvanced Solid Tumor+2 more
Alterome Therapeutics, Inc.110 enrolled51 locationsNCT06533059
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca744 enrolled302 locationsNCT06417814
Recruiting
DESTINY-PANTUMOUR04
Liver CancerEsophageal CancerPancreatic Cancer+24 more
AstraZeneca100 enrolled15 locationsNCT07124000
Recruiting
Phase 3
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
AstraZeneca860 enrolled264 locationsNCT05211895
Recruiting
Phase 1Phase 2
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Colorectal CarcinomaBladder CancerSolid Tumor Malignancies+2 more
Tasca Therapeutics150 enrolled13 locationsNCT07030257
Recruiting
Phase 1
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Ovarian CancerCervical CancerEndometrial Cancer+6 more
Normunity AccelCo, Inc.150 enrolled9 locationsNCT07182149
Recruiting
GEMINI-NSCLC: NSCLC Biomarker Study
Tempus AI1,200 enrolled58 locationsNCT05236114
Recruiting
Phase 1Phase 2
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Head and Neck CarcinomaLung CancerAdenoid Cystic Carcinoma
VM Oncology, LLC242 enrolled15 locationsNCT03556228
Recruiting
Phase 2
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Metastatic Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerRecurrent Breast Cancer
Puma Biotechnology, Inc.150 enrolled53 locationsNCT06369285
Recruiting
Phase 3
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8+2 more
SWOG Cancer Research Network2,400 enrolled963 locationsNCT05929768
Recruiting
Phase 3
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
AstraZeneca280 enrolled105 locationsNCT06008093
Recruiting
Pan-tumor MRD Study
Esophageal CancerMelanoma (Skin Cancer)NSCLC (Non-small Cell Lung Cancer)+4 more
Paradigm Health1,350 enrolled2 locationsNCT06605404
Recruiting
Not Applicable
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Anatomic Stage IV Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8HER2/Neu Negative+3 more
SWOG Cancer Research Network739 enrolled723 locationsNCT03723928